Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Fruquintinib boosts survival in mCRC patients
August 2018
SHARING OPTIONS:

As announced recently by the Journal of the American Medical Association, there was good news from a randomized clinical trial of fruquintinib in 416 Chinese patients with metastatic colorectal cancer (mCRC) who had seen their cancer progress after at least two lines of chemotherapy: fruquintinib treatment led to a statistically significant increase in patients’ overall survival compared to placebo. Patients who received oral fruquintinib in the FRESCO trial had a median survival time of 9.3 months, compared to 6.6 months in the placebo arm. Median progression-free survival (PFS) improved as well, with fruquintinib patients displaying a median PFS of 3.7 months vs. 1.8 months in the placebo arm. About 61.2 percent of patients receiving fruquintinib experienced grades 3 and 4 treatment-emergent adverse events, with 15.5 percent reporting serious adverse events and 14.4 percent requiring hospitalization.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.